Sarepta Therapeutics (SRPT) Receivables - Net (2010 - 2026)

Sarepta Therapeutics' Receivables - Net history runs 17 years deep, the most recent figure standing at $394.8 million for Q1 2026.

• In Q1 2026, Receivables - Net fell 40.12% year-over-year to $394.8 million; the TTM figure through Mar 2026 stood at $394.8 million (down 40.12% YoY), while the FY2025 annual figure was $398.2 million, down 33.85% from the prior year.
• Receivables - Net for Q1 2026 stood at $394.8 million, down from $398.2 million in the prior quarter.
• The five-year high for Receivables - Net was $659.4 million in Q1 2025, with the low at $178.2 million in Q1 2022.
• The 5-year median for Receivables - Net is $378.8 million (2024), against an average of $360.5 million.
• The sharpest annual moves came in 2023 and 2026: Receivables - Net surged 86.55% in 2023, then slumped 40.12% in 2026.
• Sarepta Therapeutics' Receivables - Net stood at $214.6 million in 2022, then soared by 86.55% to $400.3 million in 2023, then soared by 50.37% to $602.0 million in 2024, then tumbled by 33.85% to $398.2 million in 2025, then declined by 0.85% to $394.8 million in 2026.
• Business Quant data shows SRPT's Receivables - Net at $394.8 million in Q1 2026, $398.2 million in Q4 2025, and $395.7 million in Q3 2025.